Equities Analysts Offer Predictions for CRDF Q3 Earnings

Key Points

• Zacks Research raised its Q3 2026 EPS estimate for Cardiff Oncology to a loss of $0.15 per share from a previous forecasted loss of $0.18. Full-year 2026 estimates indicate a loss of approximately $0.64 per share.
• Analyst sentiment has weakened, with several brokerages downgrading the stock; Cardiff currently has an average “Hold” rating and a $7.50 price target.
• Cardiff reported a Q2 loss of $0.14 per share, missing expectations by $0.02, while the stock opened at $0.90 and remained near its 52-week low. Company insiders recently bought shares, and insiders own 8.50% of the company.

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities researchers at Zacks Research increased their Q3 2026 EPS estimates for Cardiff Oncology in a research note issued on Monday, August 17th. Zacks Research analyst J. Vandermosten now anticipates that the company will earn ($0.15) per share for the quarter, up from their previous forecast of ($0.18). The consensus estimate for Cardiff Oncology's current full-year earnings is ($0.65) per share. Zacks Research also issued estimates for Cardiff Oncology's Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.55) EPS.

A number of other brokerages also recently weighed in on CRDF. TD Cowen lowered Cardiff Oncology from a "buy" rating to a "hold" rating in a report on Monday, June 1st. William Blair downgraded Cardiff Oncology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, August 11th. HC Wainwright lowered Cardiff Oncology from a "buy" rating to a "neutral" rating in a report on Monday, June 1st. Weiss Ratings raised Cardiff Oncology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen downgraded Cardiff Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $7.50.

Cardiff Oncology Stock Performance

NASDAQ:CRDF opened at $0.90 on Thursday. The firm has a market cap of $69.85 million, a price-to-earnings ratio of -1.50 and a beta of 1.49. Cardiff Oncology has a 52 week low of $0.76 and a 52 week high of $3.31. The firm has a 50-day moving average price of $1.10 and a two-hundred day moving average price of $1.49.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.The firm had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.06 million.

Insider Activity at Cardiff Oncology

In related news, Director Gary W. Pace purchased 30,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The shares were bought at an average price of $1.22 per share, with a total value of $36,600.00. Following the acquisition, the director owned 1,356,376 shares of the company's stock, valued at $1,654,778.72. This trade represents a 2.26% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mani Mohindru purchased 24,703 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was bought at an average cost of $1.21 per share, for a total transaction of $29,890.63. Following the acquisition, the chief executive officer directly owned 24,703 shares in the company, valued at $29,890.63. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 8.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Laurion Capital Management LP raised its stake in Cardiff Oncology by 7.3% in the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company's stock valued at $7,437,000 after acquiring an additional 180,866 shares during the period. Acorn Capital Advisors LLC boosted its position in Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company's stock worth $4,042,000 after purchasing an additional 553,317 shares during the period. Geode Capital Management LLC increased its stake in shares of Cardiff Oncology by 7.5% in the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company's stock worth $4,723,000 after purchasing an additional 104,409 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of Cardiff Oncology in the fourth quarter worth about $3,388,000. Finally, State Street Corp raised its position in shares of Cardiff Oncology by 4.0% in the fourth quarter. State Street Corp now owns 1,191,647 shares of the company's stock valued at $3,349,000 after purchasing an additional 45,288 shares during the period. Institutional investors own 16.29% of the company's stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff's pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source